financetom
Business
financetom
/
Business
/
Bandhan Bank Q2 profit down 5% at Rs 920 cr
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bandhan Bank Q2 profit down 5% at Rs 920 cr
Nov 2, 2020 6:16 AM

Bandhan Bank on Monday reported 5.3 percent decline in net profit at Rs 920 crore for September quarter of the current fiscal year. The bank clocked a net profit of Rs 971.80 crore in the same period of 2019-20.

Total income grew 22 percent to Rs 2,304.90 crore in July-September 2020-21 as against Rs 1,889.30 crore in the year-ago period, Bandhan Bank said in a regulatory filing. Net interest income of the Kolkata-headquartered lender jumped 25.8 percent to Rs 1,923.1 crore during the quarter while the non-interest income grew 6.1 percent to Rs 381.8 crore.

Bandhan Bank said it has reported the highest ever quarterly profit before tax at Rs 1,233 crore during the period under review. Net Interest Margin (annualised) in the quarter fell to 8 percent against 8.2 percent in year-ago period. During the quarter, the bank took accelerated additional provision on standard advances amounting to Rs 300 crore. With this provision and the additional standard assets provision that bank is carrying in micro banking portfolio, the total additional provision in books stands at Rs 2,096 crore, it said.

The bank’s gross non-performing assets fell to 1.2 percent (Rs 874 crore) of gross advances as of September 30, 2020 as against 1.8 percent (Rs 1,064.20 crore) by the year-ago same period. Net NPAs too improved to 0.4 percent (Rs 262.50 crore) from 0.6 percent (Rs 336.90 crore).

”As the moratorium ended on 31st August 2020 coupled with robust rural performance, we have seen an all-round improvement in collection, disbursement and deposits. On deposits front, we have witnessed the best ever quarter whereas on the disbursement front, we are close to pre-COVID-19 level.”

Collections have seen a steady improvement month-on-month and is expected to reach near normal in the next 90 days. We now look forward to accelerate the business in H2FY 21,” Managing Director and CEO Chandra Shekhar Ghosh said. Total Advances grew 19.4 percent to Rs 76,614.6 crore as on September 30, 2020. Total deposits increased 34.4 percent to Rs 66,127.7 crore.

Bandhan Bank stock was trading at Rs 305.50 on BSE, up 5.62 percent from the previous close.

First Published:Nov 2, 2020 3:16 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
X-energy, Talen to explore deploying small modular reactors for PJM power market
X-energy, Talen to explore deploying small modular reactors for PJM power market
Mar 19, 2026
March 19 (Reuters) - X-energy Reactor Company and Talen Energy ( TLN ) have agreed to explore deploying X-energy's small modular reactors in Pennsylvania and across the PJM power market, the companies said on Thursday. The U.S. nuclear industry is undergoing a renaissance after years of stagnation, primarily driven by surging power demand from the massive computing infrastructure required for...
What's Going On With Smart Powerr Stock Thursday?
What's Going On With Smart Powerr Stock Thursday?
Mar 19, 2026
Smart Powerr Corp. ( CREG ) is under pressure on Thursday with no company-specific news to explain the move. The decline appears to be driven by broader market weakness, with the Nasdaq off 1.17% and the S&P 500 down 0.78% on the session. The company Smart Powerr ( CREG ) focuses on recycling waste energy and improving efficiency in China's...
Eli Lilly Says Experimental Diabetes Drug Shows Weight Loss Of 17%
Eli Lilly Says Experimental Diabetes Drug Shows Weight Loss Of 17%
Mar 19, 2026
Eli Lilly and Co ( LLY ) shares are down on Thursday. The company released news regarding its investigational drug, retatrutide, which has shown promising results in clinical trials. Eli Lilly Retatrutide Shows Strong A1C Reduction And Weight Loss Retatrutide is an investigational once-weekly triple hormone receptor agonist that activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1...
Embecta Rallies After UK Firm Deal Worth $200 Million
Embecta Rallies After UK Firm Deal Worth $200 Million
Mar 19, 2026
Embecta Corp. ( EMBC ) shares are up on Thursday after the company agreed to acquire Owen Mumford Holdings Limited. This strategic move aims to enhance Embecta’s capabilities in drug-delivery systems. Deal Valued At Up To $200 Million Embecta ( EMBC ) values the acquisition at up to 150 million pounds (around $200.1 million). That includes an upfront cash payment...
Copyright 2023-2026 - www.financetom.com All Rights Reserved